A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation

被引:54
作者
Chiou, Herbert [1 ]
Chan, Hak-Kim [1 ]
Heng, Desmond [1 ]
Prud'homme, Robert K. [2 ]
Raper, Judy A. [3 ]
机构
[1] Univ Sydney, Fac Pharm, Adv Drug Delivery Grp, Sydney, NSW 2006, Australia
[2] Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA
[3] Univ Missouri, Dept Chem & Biol Engn, Rolla, MO 65409 USA
基金
澳大利亚研究理事会; 美国国家科学基金会;
关键词
confined liquid impinging jet; cyclosporine A (CsA); inhalation drug delivery; dry powder dispersion;
D O I
10.1016/j.jaerosci.2008.02.002
中图分类号
TQ [化学工业];
学科分类号
0817 [化学工程与技术];
摘要
The aim of this work is to evaluate and optimise aerosol performance of precipitated cyclosporine A (CsA) powders as a model peptide for inhalation drug delivery. Confined liquid impinging jets (CLIJ) was used to precipitate CsA with stabilisers (lecithin and lactose), followed by spray drying to produce dry powders. Minimum concentrations of each stabiliser were determined from a matrix design of nine experimental conditions (i.e. 32 corresponding to 2 additives at 3 concentration levels). Suspensions of CsA particles of 180-700 nm were produced by CLIJ precipitation and powders comprising approximately 1 mu m agglomerates of CsA particles were obtained following spray drying. The internal structure of the agglomerates was not hollow. The aerosol performance of the CLIJ-spray dried powders was initially screened using a dry powder attachment on a laser diffractometer to identify the optimal CLIJ experimental conditions. The optimal aerosol performance was then confirmed using the Aeroliser (R) dry powder inhaler with a multi-stage liquid impinger operating at 60 and 100 L/min. The powder produced from spray drying of the suspension using CLIJ at 1% w/v lactose and 0.025% w/v lecithin showed the best dispersion behaviour and the corresponding aerosol performance shows a fine particle fraction of 54-56%. These results showed the potential of CLIJ precipitation with spray drying in the production of peptides for inhalation. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:500 / 509
页数:10
相关论文
共 25 条
[1]
New technologies for the precipitation of solid particles with controlled properties [J].
Bénet, N ;
Muhr, H ;
Plasari, E ;
Rousseaux, JM .
POWDER TECHNOLOGY, 2002, 128 (2-3) :93-98
[2]
Influence of mechanical activation on the physical stability of salbutamol sulphate [J].
Brodka-Pfeiffer, K ;
Langguth, P ;
Grass, P ;
Häusler, H .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 56 (03) :393-400
[4]
Crystallization of amorphous components in spray-dried powders [J].
Chiou, D. ;
Langrish, T. A. G. .
DRYING TECHNOLOGY, 2007, 25 (09) :1427-1435
[5]
Chiou H, 2008, DRUG DEV IND PHARM, V34, P59, DOI [10.1080/03639040701508011, 10.1080/03639040701508011 ]
[6]
Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation [J].
Chiou, Herbert ;
Li, Li ;
Hu, Tingting ;
Chan, Hak-Kim ;
Chen, Jian-Feng ;
Yun, Jimmy .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 331 (01) :93-98
[7]
Clark A, 2002, LUNG BIOL HEALTH DIS, V162, P105
[8]
Preservation of post-transplant lung function with aerosol cyclosporin [J].
Corcoran, TE ;
Smaldone, GC ;
Dauber, JH ;
Smith, DA ;
McCurry, KR ;
Burckart, GJ ;
Zeevi, A ;
Griffith, BP ;
Iacono, AT .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (03) :378-383
[9]
de Waterbeemd H. Van, 2003, DRUG BIOAVAILABILITY
[10]
Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients [J].
Galeazzi, Mauro ;
Bellisai, Francesca ;
Manganelli, Stetania ;
Morozzi, Gabriella ;
Sebastiani, Gian Domenico .
AUTOIMMUNITY REVIEWS, 2006, 5 (07) :493-498